147,161 research outputs found
Author Correction: Evaluation of skin cancer resection guide using hyper‑realistic in‑vitro phantom fabricated by 3D printing
No full textThe original version of this Article contained an error in the spelling of the author Taehun Kim which was incorrectly given as Teahun Kim. The original Article has been corrected
Measurement of the ratio of prompt χ c to J / ψ production in pp collisions at √s = 7 TeV
No full textThe prompt production of charmonium χ c and J / ψ states is studied in proton-proton collisions at a centre-of-mass energy of √s = 7 TeV at the Large Hadron Collider. The χ c and J / ψ mesons are identified through their decays χ c → J / ψ γ and J / ψ → μ + μ - using 36 pb - 1 of data collected by the LHCb detector in 2010. The ratio of the prompt production cross-sections for χ c and J / ψ, σ (χ c → J / ψ γ) / σ (J / ψ), is determined as a function of the J / ψ transverse momentum in the range 2 < p T J / ψ < 15 GeV / c. The results are in excellent agreement with next-to-leading order non-relativistic expectations and show a significant discrepancy compared with the colour singlet model prediction at leading order, especially in the low p T J / ψ region
Evidence for the decay B0→J/ψω and measurement of the relative branching fractions of meson decays to J/ψη and J/ψη′
No full textFirst evidence of the B 0 → J / ψ ω decay is found and the B s 0 → J / ψ η and B s 0 → J / ψ η ′ decays are studied using a dataset corresponding to an integrated luminosity of 1.0 fb -1 collected by the LHCb experiment in proton-proton collisions at a centre-of-mass energy of sqrt(s) = 7 TeV. The branching fractions of these decays are measured relative to that of the B 0 → J / ψ ρ 0 decay:frac(B (B 0 → J / ψ ω), B (B 0 → J / ψ ρ 0)) = 0.89 ± 0.19 (stat) - 0.13 + 0.07 (syst),frac(B (B s 0 → J / ψ η), B (B 0 → J / ψ ρ 0)) = 14.0 ± 1.2 (stat) - 1.5 + 1.1 (syst) - 1.0 + 1.1 (frac(f d, f s)),frac(B (B s 0 → J / ψ η ′), B (B 0 → J / ψ ρ 0)) = 12.7 ± 1.1 (stat) - 1.3 + 0.5 (syst) - 0.9 + 1.0 (frac(f d, f s)), where the last uncertainty is due to the knowledge of f d / f s, the ratio of b-quark hadronization factors that accounts for the different production rate of B 0 and B s 0 mesons. The ratio of the branching fractions of B s 0 → J / ψ η ′ and B s 0 → J / ψ η decays is measured to befrac(B (B s 0 → J / ψ η ′), B (B s 0 → J / ψ η)) = 0.90 ± 0.09 (stat) - 0.02 + 0.06 (syst)
Possible evidence for an inverted temperature–density relation in the intergalactic medium from the flux distribution of the Lyα forest
No full textWe compare the improved measurement of the Ly alpha forest flux probability distribution at 1.7 < z < 3.2 presented by Kim et al. to a large set of hydrodynamical simulations of the Ly alpha forest with different cosmological parameters and thermal histories. The simulations are in good agreement with the observational data if the temperature-density relation for the low-density intergalactic medium (IGM), T= T(0)Delta(gamma-1), is either close to isothermal or inverted (gamma < 1). Our results suggest that the voids in the IGM may be significantly hotter and the thermal state of the low-density IGM may be substantially more complex than is usually assumed at these redshifts. We discuss radiative transfer effects which alter the spectral shape of ionizing radiation during the epoch of He II reionization as a possible physical mechanism for achieving an inverted temperature-density relation at z similar or equal to 3
Strong magnetic field dependence of critical current densities and vortex activation energies in an anisotropic clean MgB2 thin film
No full textWe report the influence of two-band superconductivity on the flux creep and the critical current densities of a MgB2 thin film. The small magnetic penetration depth of lambda=50 +/- 10 nm at T=4 K is related to a clean pi-band. We find a high self-field critical current density J(C), which is strongly reduced with applied magnetic field, and attribute this to suppression of the superconductivity in the pi-band. The temperature dependence of the creep rate S (T) at low magnetic field can be explained by a simple Anderson-Kim mechanism. The system shows high pinning energies at low field that are strongly suppressed by high field. (C) 2014 Elsevier Ltd. All rights reserved.X1112Ysciescopu
Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma
No full textPatients and methods: We collected 64 NKTCL cases and numerically quantified the amount of tumor-infiltrating FOXP3-positive Tregs by automated slide scanning and image analysis program after immunohistochemical staining using anti-FOXP3 antibody. Results: Patients were able to be classified into two end groups by their level of Tregs. Twenty-eight (44%) patients had Tregs < 50/0.40 mm(2), while 36 (56%) had Tregs >= 50/0.40 mm(2) within the tumor. The decreased number of Tregs (< 50/0.40 mm(2)) was more common in patients with poor performance status or in those presented in non-upper aerodigestive tract. However, the level of Tregs was not associated with other prognostic factors, including stage, lactate dehydrogenase level, International Prognostic Index, and NKTCL Prognostic Index. Importantly, patients with increased numbers of Tregs (>= 50/0.40 mm(2)) showed prolonged overall and progression-free survival (P = 0.0005 and P = 0.0079, respectively). The number of FOXP3-positive Tregs was an independent prognostic factor (P = 0.001) by multivariate analysis. Conclusion: Increased quantity of tumor-infiltrating Tregs predicted improved clinical outcome in NKTCL patients.Kim TM, 2008, ANN ONCOL, V19, P1477, DOI 10.1093/annonc/mdn147Baumforth KRN, 2008, AM J PATHOL, V173, P195, DOI 10.2353/ajpath.2008.070845Mittal S, 2008, BLOOD, V111, P5359, DOI 10.1182/blood-2007-08-105395Lee NR, 2008, LEUKEMIA LYMPHOMA, V49, P247, DOI 10.1080/10428190701824536CHAN JKC, 2008, WHO CLASSIFICATION T, P285Gjerdrum LM, 2007, LEUKEMIA, V21, P2512, DOI 10.1038/sj.leu.2404913Kim SJ, 2007, ANN ONCOL, V18, P1382, DOI 10.1093/annonc/mdm183Pai S, 2007, IMMUNOL CELL BIOL, V85, P370, DOI 10.1038/sj.icb.7100046Hasselblom S, 2007, BRIT J HAEMATOL, V137, P364, DOI 10.1111/j.1365-2141.2007.06593.xBossard C, 2007, BLOOD, V109, P2183, DOI 10.1180/blood-2006-07-033142Ralainirina N, 2007, J LEUKOCYTE BIOL, V81, P144, DOI 10.1189/jlb.0606409Shim SJ, 2007, INT J RADIAT ONCOL, V67, P31, DOI 10.1016/j.ijrobp.2006.07.1387Ghiringhelli F, 2006, IMMUNOL REV, V214, P229Carreras J, 2006, BLOOD, V108, P2957, DOI 10.1182/blood-2006-04-018218Lee J, 2006, J CLIN ONCOL, V24, P612, DOI 10.1200/JCO.2005.04.1384Barath S, 2006, ACTA HAEMATOL-BASEL, V116, P181, DOI 10.1159/000094678Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JC125947Kim TM, 2005, BLOOD, V106, P3785Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511Romagnani C, 2005, EUR J IMMUNOL, V35, P2452, DOI 10.1002/eji.200526069Lee J, 2005, EUR J CANCER, V41, P1402, DOI 10.1016/j.ejca.2005.03.010Alvaro T, 2005, CLIN CANCER RES, V11, P1467Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122Ichihara F, 2003, CLIN CANCER RES, V9, P4404Cheung MMC, 2002, INT J RADIAT ONCOL, V54, P182Woo EY, 2001, CANCER RES, V61, P4766Ho JWY, 1999, J CLIN PATHOL-MOL PA, V52, P269Kagami Y, 1998, BRIT J HAEMATOL, V103, P669Boulland ML, 1998, AM J PATHOL, V153, P1229Cheung MMC, 1998, J CLIN ONCOL, V16, P706Y
Coos River Basin fish management plan
No full textprepared by Linda J. Wagoner, Kim K. Jones, Reese E. Bender, Jerry A. Butler, Darrell E. Demory, Thomas F. Gaumer, Joel A. Hurtado, William G. Mullarkey, Paul E. Reimers, Neil T. Richmond, Thomas J. Rumreich.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may not be suitable for legal purposes.Includes bibliographical references (pages 122-124).Mode of access: Internet from the Oregon Government Publications Collection.Text in English
Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone
No full textBackground: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy. Patients and methods: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks. Results: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0-1 in thirteen, 2 in five, 3 in five, and 4-5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7% of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia. Conclusions: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection.Lee KW, 2006, LEUKEMIA LYMPHOMA, V47, P1274, DOI 10.1080/10428190600562823Kim HJ, 2006, BONE MARROW TRANSPL, V37, P819, DOI 10.1038/sj.bmt.1705349Suzuki R, 2006, BONE MARROW TRANSPL, V37, P425, DOI 10.1038/sj.bmt.1705244Kim TM, 2005, BLOOD, V106, P3785You JY, 2004, ANN ONCOL, V15, P618, DOI 10.1093/annonc/mdh143Li CC, 2004, CANCER, V100, P366, DOI 10.1002/cncr.11908Chim CS, 2004, BLOOD, V103, P216, DOI 10.1182/blood-2003-05-1401Kim BS, 2003, ACTA ONCOL, V42, P779, DOI 10.1080/02841860310010682Yong WB, 2003, INT J HEMATOL, V78, P163Matsumoto Y, 2003, LEUKEMIA LYMPHOMA, V44, P879, DOI 10.1080/1042819031000067873Nagafuji K, 2001, INT J HEMATOL, V74, P447Shikama N, 2001, INT J RADIAT ONCOL, V51, P1228Ribrag V, 2001, LEUKEMIA, V15, P1123Kim WS, 2001, ANN ONCOL, V12, P349YAMAGUCHI M, 2001, J CLIN EXP HEMATOPAT, V41, P93Rodriguez J, 2000, LEUKEMIA LYMPHOMA, V39, P139Kim GE, 2000, J CLIN ONCOL, V18, P54Ko YH, 1998, CANCER, V83, P806Li YX, 1998, CANCER, V83, P449Cheung MMC, 1998, J CLIN ONCOL, V16, P70Logsdon MD, 1997, CANCER, V80, P477Shikama N, 1997, RADIOLOGY, V204, P467Kwong YL, 1997, BRIT J HAEMATOL, V97, P821CHAN JKC, 1997, BLOOD, V9, P4501Jaffe ES, 1996, AM J SURG PATHOL, V20, P103Chen HHW, 1996, RADIOTHER ONCOL, V38, P1LIANG R, 1995, J CLIN ONCOL, V13, P666CHAN JKC, 1994, AM J SURG PATHOL, V18, P938VELASQUEZ WS, 1994, J CLIN ONCOL, V12, P1169ARBER DA, 1993, AM J SURG PATHOL, V17, P392SOBREVILLACALVO P, 1993, ACTA ONCOL, V32, P69SMALLEY SR, 1988, INT J RADIAT ONCOL, V15, P599VELASQUEZ WS, 1988, BLOOD, V71, P117CABANILLAS F, 1982, BLOOD, V60, P6939Y
CIS TRANS ISOMERIZATION AND STRUCTURE OF DIMERIC [ME2GA(MU-NH(T)BU)]2
No full textThe reaction of GaMe3 with tBuNH2 at 110-degrees-C affords a mixture of trans- (1a) and cis-[Me2Ga(mu-NHtBu)]2 (1b) which crystallizes as pure 1a in 75% yield. H-1 NMR study shows that the dimeric amido complex undergoes a cis-trans isomerization (1a --> 1b) in solution. The equilibrium has been observed to follow reversible first-order kinetics with DELTAH-degrees = 3.12 +/- 0.04 kJ mol-1 and DELTAS-degrees = 4.56 +/- 0.06 J mol-1 K-1. The activation parameters for the conversion 1a --> 1b are DELTAH-1 = 120.8 +/- 7.4 kJ mol-1 and DELTAS1 = 41.4 +/- 2.6 J mol-1 K-1 and for the reverse reaction 1b --> 1a are DELTAH-1 = 117.8 +/- 7.9 kJ mol-1 and DELTAS-1 = 37.3 +/- 2.5 J mol-1 K-1. The isomerization is markedly accelerated in the presence of pyridine. A crossover experiment indicates that the isomer interconversion is a unimolecular process. On the basis of these data, a possible pathway for the isomerization is proposed. The molecular structure of 1a has been determined by a single-crystal X-ray diffraction study. The molecular geometry of 1a consists of a centrosymmetric and dimeric unit with two bridging amido groups and two terminal methyl groups bound to each gallium atom. The two N-(t)Bu groups are trans to each other with respect to the (Ga-N)2 ring. The coordination geometry of both the gallium and nitrogen atoms is distorted tetrahedral
Three-transistor one-time programmable (OTP) ROM cell array using standard CMOS gate oxide antifuse
No full textA three-transistor (3-T) cell CMOS one-time programmable (OTP) ROM array using CMOS antifuse (AF) based on permanent breakdown of MOSFET gate oxide is proposed, fabricated and characterized. The proposed 3-T OTP cell for ROM array is composed of an nMOS AF, a high-voltage blocking nMOS, and cell access transistor, all compatible with standard CMOS technology. The experimental results show that the proposed structure can be a viable technology option of high-density CMOS OTP ROM array for modern digital as well as analog circuits.The authors appreciate useful discussion with Dr. K. Kim at
Samsung Electronics Co. Ltd. and careful reviewers’ comment
- …
